BioPharma Credit Ord clears the business-activity screen and the figures we can measure look clean, but its debt figure is still pending, so the verdict is not final yet.
BioPharma Credit Ord
BPCR.L · LSE · USD · Market cap $1.1B
Not yet scoredPrice as of 13 Nov 2026Daily close, not a live quote
Screened 2026-11-13 · the tape above runs as of 08:09 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price0.99 USD at the 13 Nov 2026 close
- Our regime readAccumulation, as of 15 Nov 2026
- Ethical screenNot yet scored
- Last reviewed13 Nov 2026 (3 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: range not available (screen dated 2026-11-13).
- Trend Accumulation
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical screen not yet scored
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its accumulation label.
BioPharma Credit Ord holds its Accumulation at $0.99. The statistical read favours the buyers, held for 1 days.
| Phase | Accumulation |
| Quantitative state | The statistical read favours the buyers, held for 1 days |
| Price at the screen | $0.99 |
| Valuation | 9.68 trailing · N/A forward price to earnings |
| Values screen | Not scored · score 70.0 |
Five Screens, Shown in Full
This security has not been fully scored against the values screen yet.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | Excluded | Below 33% | Interest-bearing debt is of its assets, above the one-third ceiling the screen allows. | Fail |
| Interest-bearing cash | 0.00% | Below 33% | Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. | Pass |
| Receivables | 5.66% | Below 49% | Money owed to the company is 5.7% of assets, under the 49% limit. | Pass |
| Revenue purity | 1.23% | Below 5% | Only 1.2% of revenue comes from non-compliant sources, under the 5% line. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadThe Read, in Plain English
BioPharma Credit Ord clears the business-activity screen and the figures we can measure look clean, but its debt figure is still pending, so the verdict is not final yet.
Read as at 2026-11-15. It updates when the underlying figures move, and past reads are kept below.
We do not yet have the financial statements needed to run the debt, cash, receivables and income screens for BioPharma Credit Ord, so it is not scored yet.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
The Business, in Plain Words| Trailing P/E | 9.7xvery cheap relative to earnings |
| Dividend yield | 7.25% |
| 52-week range | 0.88 - 1.00 |
| Market cap | $1.1B |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeBPCR.L trades on LSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 1.2% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 5%.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.6% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 6% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 5%.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 1.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 6% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 5%.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 5%.
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 0.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 5%.
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 5%.
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 1.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 5%.
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 21%. Our forward projection puts the odds of a 10% gain over the next month near 5%.
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Is BioPharma Credit (LSE:BPCR) Trading Below Fair Value Today? Yahoo Finance · 10d ago
- BioPharma Credit (LSE:BPCR) Stock Could Be 34% Below Fair Value On Returns Yahoo Finance · 16 Oct 2026
- What BioPharma Credit (BPCP) Said on Its H1 Earnings Call Yahoo Finance · 25 Sep 2026
- Science Group And 2 Other Undiscovered Gems in the United Kingdom Simply Wall St. · 1 Jun 2026
- Science Group And 2 Other Undiscovered Gems in the United Kingdom Yahoo Finance · 1 Jun 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $0.94 | +1.1% | · | $1,011 | +1.1% |
| 2 months | $0.92 | +3.0% | $0.02 | $1,049 | +4.9% |
| 3 months | $0.93 | +2.3% | $0.02 | $1,042 | +4.2% |
| 6 months | $0.86 | +10.0% | $0.05 | $1,157 | +15.7% |
| 1 year | $0.79 | +20.6% | $0.10 | $1,332 | +33.2% |
| 2 years | $0.68 | +40.7% | $0.20 | $1,705 | +70.5% |
| 3 years | $0.65 | +46.4% | $0.30 | $1,932 | +93.2% |
| 5 years | $0.56 | +70.7% | $0.50 | $2,612 | +161.2% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever BPCR.L does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.